RUPATADINE IN ALLERGIC RHINITIS AND CHRONIC URTICARIA

Abstract

Histamine is the primary mediator involved in the pathophysiology of allergic rhinitis and chronic urticaria, and this explains the prominent role that histamine H1-receptor antagonists have in the treatment of these disorders. However, histamine is clearly not the only mediator involved in the inflammatory cascade. Drugs which can inhibit a broader range of inflammatory processes may prove to be more effective in providing symptomatic relief in both allergic rhinitis and chronic urticaria. Rupatadine, a newer dual inhibitor of histamine H1- and PAF-receptors, includes anti-inflammatory effects in addition to a powerful inhibition of H1- and PAF-receptors. It has a fast onset of action, producing rapid symptomatic relief and has an extended duration of clinical activity which allows once-daily administration. Rupatadine is effective as drugs such as loratadine, cetirizine, desloratadine and ebastine in reducing allergic symptoms in adult allergic rhinitis has no adverse cardiovascular effects, nor negative significant effects on cognition, psychomotor performance and improves the overall well-being of allergic rhinitis or CIU patients.